DJIA 17,086.63 -26.91 -0.16%
NASDAQ 4,473.70 17.68 0.40%
S&P 500 1,987.01 3.48 0.18%
market minute promo

Durata Therapeutics (NASDAQ: DRTX)

14.33 -0.31 (-2.12%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

DRTX $14.33 -2.12%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $14.65
Previous Close $14.64
Daily Range $14.26 - $14.88
52-Week Range $7.72 - $18.17
Market Cap $381.8M
P/E Ratio -5.95
Dividend (Yield) $0.00 (0.0%)
Volume 173,765
Average Daily Volume 278,243
Current FY EPS -$2.74





Durata Therapeutics (DRTX) Description

Durata Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Website:

News & Commentary Rss Feed

3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata

A video looking at upcoming FDA decisions for Chelsea Therapeutics, MannKind, and Durata Therapeutics.

Durata Therapeutics Announces US Launch of Dalvance

Commit To Buy Durata Therapeutics At $15, Earn 24.6% Annualized Using Options

Cubist Gains FDA Approval for Sivextro - Analyst Blog

Durata Therapeutics' Skin Drug Gets FDA Nod - Analyst Blog

Durata Therapeutics' Skin Drug Gets FDA Nod - Analyst Blog

Orexigen Will Run: Here's Why

Sector Update: Healthcare Stocks Higher Pre-Market; Durata Sinks 11% After Strong Rally

Sector Update: Healthcare

Benzinga's Top #PreMarket Losers

Stocks To Watch For May 27, 2014

Durata Confirms FDA Approval of DALVANCE for Skin Infections

See More DRTX News...